UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2003
Lifecore Biomedical, Inc.
(Exact name of Registrant as specified in its charter)
| | | | | |
| Minnesota | | 0-4136 | | 41-0948334 |
| |
| |
|
(State or other jurisdiction of
incorporation or organization) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | |
3515 Lyman Boulevard
Chaska, Minnesota | |
55318 |
| |
|
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: 952-368-4300
TABLE OF CONTENTS
Item 7. Financial Statements and Exhibits
(c) The following exhibit is being furnished herewith:
99.1 Press release dated October 29, 2003
Item 9. Regulation FD Disclosure
On October 29, 2003, Lifecore Biomedical, Inc. (“Lifecore”) issued a press release which announced today that it has signed an exclusive distribution agreement with Bardo-Biotech SAS (“BBS”) of Toulouse, France, to distribute Lifecore’s oral restorative products in France.
A copy of Lifecore’s press release is attached hereto as Exhibit (99.1) and hereby incorporated by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | | LIFECORE BIOMEDICAL, INC. |
| | | |
| | | |
| Dated: October 29, 2003 | | /s/ James W. Bracke |
| | |
|
| | | James W. Bracke |
| | | President & Chief Executive Officer |
Exhibit Index
99.1 Press release dated October 29, 2003
